Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4865939
Max Phase: Preclinical
Molecular Formula: C55H73F15N14O17
Molecular Weight: 917.13
Molecule Type: Unknown
Associated Items:
ID: ALA4865939
Max Phase: Preclinical
Molecular Formula: C55H73F15N14O17
Molecular Weight: 917.13
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(=O)N[C@H](CCCN)C(=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NCCN1CCN(CCC(=O)NC2CCN(CC(=O)N3c4ccccc4NC(=O)c4ccccc43)CC2)CC1.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=C(O)C(F)(F)F
Standard InChI: InChI=1S/C45H68N14O7.5C2HF3O2/c1-30(41(63)55-44(66)36(11-7-18-46)52-31(2)60)51-43(65)35(12-8-19-50-45(47)48)49-20-24-57-27-25-56(26-28-57)23-17-39(61)53-32-15-21-58(22-16-32)29-40(62)59-37-13-5-3-9-33(37)42(64)54-34-10-4-6-14-38(34)59;5*3-2(4,5)1(6)7/h3-6,9-10,13-14,30,32,35-36,49H,7-8,11-12,15-29,46H2,1-2H3,(H,51,65)(H,52,60)(H,53,61)(H,54,64)(H4,47,48,50)(H,55,63,66);5*(H,6,7)/t30-,35-,36+;;;;;/m0...../s1
Standard InChI Key: BSYIIOHLKCQPKB-PFJBEOSVSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 917.13 | Molecular Weight (Monoisotopic): 916.5395 | AlogP: -0.88 | #Rotatable Bonds: 22 |
Polar Surface Area: 292.55 | Molecular Species: BASE | HBA: 13 | HBD: 10 |
#RO5 Violations: 3 | HBA (Lipinski): 21 | HBD (Lipinski): 12 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.38 | CX Basic pKa: 11.98 | CX LogP: -3.81 | CX LogD: -8.48 |
Aromatic Rings: 2 | Heavy Atoms: 66 | QED Weighted: 0.04 | Np Likeness Score: -0.55 |
1. Weinhart CG, Wifling D, Schmidt MF, Neu E, Höring C, Clark T, Gmeiner P, Keller M.. (2021) Dibenzodiazepinone-type muscarinic receptor antagonists conjugated to basic peptides: Impact of the linker moiety and unnatural amino acids on M2R selectivity., 213 [PMID:33571911] [10.1016/j.ejmech.2021.113159] |
Source(1):